

Genicular Nerve Injection

Clinical Guidelines for Medical Necessity Review

Version:V1.0Effective Date:July 1, 2023

Important Notices

Notices & Disclaimers:

GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End UserS**". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2023 Cohere Health, Inc. All Rights Reserved.

Other Notices:

CPT copyright 2023 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

Guideline Information:

Disease Area: Cardiology Care Path Group: Not applicable Guideline Name: Genicular Nerve Injection Type: [X] Adult (18+ yo) | [_] Pediatric (0-17yo)

Physician author: Dr. Vijay Yanamadala Peer reviewed by: Dr. Traci Granston Literature review current through: June 7, 2023 Document last updated: June 7, 2023

Table of Contents

Important Notices	2
Medical Necessity Criteria	4
Service: Genicular Nerve Injection	4
General Guidelines	4
Medical Necessity Criteria	4
Indications	4
Non-Indications	5
Site of Service Criteria	5
Procedure Codes (HCPCS/CPT)	5
References	6

Medical Necessity Criteria

Service: Genicular Nerve Injection

General Guidelines

- Units, Frequency, & Duration: When medical necessity criteria is met, a total of one set of genicular nerve blocks (to each of the three applicable genicular nerves) per side may be performed in 3 months.
- **Criteria for Subsequent Requests:** If the patient has had genicular nerve block within the last three months, a second injection may be considered. If the patient has had two or more genicular nerve blocks in the past six months and the previous injection resulted in 50% improvement of symptoms for three months, then another injection may be considered.¹
- **Recommended Clinical Approach:** Genicular nerves provide sensory innervation to your knee and include the: (1) Superolateral genicular nerve (SLGN); (2) Superomedial genicular nerve (SMGN); (3) Inferomedial genicular nerve (IMGN) and (4) Inferolateral genicular nerve (ILGN). Genicular nerve blocks are a procedure used to alleviate pain originating from the genicular nerves in the knee joint. These nerves are responsible for transmitting pain signals from the knee joint to the brain. Genicular nerve blocks are typically performed as a diagnostic tool or as a therapeutic intervention for knee pain that has not responded to conservative treatments.²⁻⁷ Physicians can safely target all of these nerves for a genicular nerve block except for the ILGN.⁸ This is because the ILGN is too close to the peroneal nerve.
- **Exclusions:** Active systemic infection, Coagulopathy or bleeding diathesis, active use of antiplatelet or anticoagulant medications, pregnancy, allergy to local anesthetics or other medications used during the procedure.

Medical Necessity Criteria

Indications

- → Genicular Nerve Injection is considered appropriate if **ANY** of the following are **TRUE**^{2,9-11}:
 - Initial Genicular Nerve injection and **ANY** of the following:
 - Documentation of failed conservative treatments (e.g., physical therapy, medications, injections) for at least 3 months.
 - The patient has **ANY** of the following conditions:

- Chronic Knee Pain
- Osteoarthritis
- Knee Injury (e.g., acute or chronic knee pain resulting from an injury, such as ligament tears, meniscal tears, or patellofemoral dysfunction)
- Previous knee surgery and have **ANY** of the following:
 - Continued pain
 - Continued functional limitations
- For patient evaluation, as a diagnostic tool to determine the source of knee pain.
- Subsequent Genicular Nerve injection and **ALL** of the following:
 - If the patient has had two or more genicular nerve blocks in the past six months
 - Previous injection resulted in 50% improvement of symptoms for three months.

Non-Indications

- → Genicular Nerve Injection may not be considered appropriate if ANY of the following are TRUE:
 - Active systemic infection.
 - Coagulopathy or bleeding diathesis.
 - Active use of antiplatelet or anticoagulant medications.
 - Pregnancy.
 - Allergy to implant materials.

Site of Service Criteria

Outpatient.

Procedure Codes (HCPCS/CPT)

HCPCS/CPT Code	Code Description/Definition
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed

References

- Ferreira-Dos-Santos G, Hurdle MB, Gupta S, Tran J, Agur AMR, Clendenen SR. Revisiting the Genicular Nerve Block: An Up-to-Date Guide Utilizing Ultrasound Guidance and Peripheral Nerve Stimulation - Anatomy Description and Technique Standardization. Pain Physician. 2021;24(2):E177-E183.
- 2. Shanahan EM, Robinson L, Lyne S, et al. Genicular Nerve Block for Pain Management in Patients With Knee Osteoarthritis: A Randomized Placebo-Controlled Trial. Arthritis Rheumatol. 2023;75(2):201-209. doi:10.1002/art.42384
- 3. Kim DH, Choi SS, Yoon SH, et al. Ultrasound-Guided Genicular Nerve Block for Knee Osteoarthritis: A Double-Blind, Randomized Controlled Trial of Local Anesthetic Alone or in Combination with Corticosteroid. Pain Physician. 2018;21(1):41-52.
- 4. Kim DH, Lee MS, Lee S, Yoon SH, Shin JW, Choi SS. A Prospective Randomized Comparison of the Efficacy of Ultrasound- vs Fluoroscopy-Guided Genicular Nerve Block for Chronic Knee Osteoarthritis. Pain Physician. 2019;22(2):139-146.
- Güler T, Yurdakul FG, Önder ME, et al. Ultrasound-guided genicular nerve block versus physical therapy for chronic knee osteoarthritis: a prospective randomised study. Rheumatol Int. 2022;42(4):591-600. doi:10.1007/s00296-022-05101-8
- Fonkoue L, Steyaert A, Kouame JK, et al. A Comparison of Genicular Nerve Blockade With Corticosteroids Using Either Classical Anatomical Targets vs Revised Targets for Pain and Function in Knee Osteoarthritis: A Double-Blind, Randomized Controlled Trial. Pain Med. 2021;22(5):1116-1126. doi:10.1093/pm/pnab014
- Tan YL, Neo EJR, Wee TC. Ultrasound-guided Genicular Nerve Blockade With Pharmacological Agents for Chronic Knee Osteoarthritis: A Systematic Review. Pain Physician. 2022;25(4):E489-E502.
- Henry S, Best TM, Jose J, Tiu T. Procedural Approach to Ultrasound-Guided Geniculate Nerve Blockade for Knee Pain in Patients with OA. Curr Sports Med Rep. 2022;21(6):192-195. Published 2022 Jun 1. doi:10.1249/JSR.000000000000965
- Kampitak W, Kertkiatkachorn W, Ngarmukos S, Tanavalee A, Tanavalee C, Tangkittithaworn C. Comparison of Analgesic Efficacies of the iPACK (Interspace Between the Popliteal Artery and Capsule of the Posterior Knee) and Genicular Nerve Blocks Used in Combination With the Continuous Adductor Canal Block After Total Knee Arthroplasty: A Randomized Clinical Trial [published online ahead of print, 2023 Mar 15]. J Arthroplasty. 2023;S0883-5403(23)00254-1. doi:10.1016/j.arth.2023.03.018
- 10. Kose SG, Kose HC, Celikel F, Akkaya OT. Predictive factors associated with successful response to utrasound guided genicular radiofrequency

ablation. Korean J Pain. 2022;35(4):447-457. doi:10.3344/kjp.2022.35.4.447

 Zaragoza G, Solorzano-Flores SY, Pineda C, Soto-Fajardo C. Ultrasound-guided genicular nerve block a new treatment in rheumatology for knee osteoarthritis pain. Rheumatol Int. 2022;42(9):1663-1664. doi:10.1007/s00296-022-05162-9